Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
134.60 K
Value Traded
2.55 M
Short % Float
1.69%
Days to Cover
1.0
+25.83%Week
+3.86%1 Month
-53.8%3 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
165.66 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
142.73 M
Total Shares
8.44 M
Float Shares
8.41 M
Insiders
10.87%
Institutions
23.49%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
YARW Catalyst Timeline
Dated clinical, regulatory and corporate events for Yarrow Bioscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Yarrow Bioscience, Inc.
25Total events
9Upcoming
6Tier-1 (high impact)
2026 to 2030Coverage
Upcoming catalysts 2
Event history 14
▼Equity OfferingCorporate
Closing of $172.5M underwritten public offering including full exercise of underwriters' option
▼Equity OfferingCorporate
Pricing of $150 million underwritten public offering of 5,769,231 shares at $26.00 per share
▼Equity OfferingCorporate
Yarrow Bioscience commences underwritten public offering of common stock and pre-funded warrants
●Corporate ApprovalCorporate
Form S-3 shelf registration statement declared effective by the SEC
▲First Patient DosedYB-101Trial
First patient dosed in Phase 2a portion of DIRECTION-GD
Graves' diseasesource ↗
▲Fast Track DesignationYB-101Designation
FDA granted Fast Track Designation for YB-101 in Graves' disease
Graves' diseasesource ↗
●Trial InitiationYB-101Trial
Initiation of Phase 2a/2b trial of YB-101 in Graves' disease
Graves' disease (with or without thyroid eye disease)source ↗
▲AcquiredCorporate
Completed reverse merger with VYNE Therapeutics and commenced Nasdaq trading
Past FDA Catalysts and PDUFA Decisions
How YARW actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 77%
Micro Cap(rank 514 of 667)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YB-101 BiologicsNCT07682896 | Graves' Disease | Phase 2 | RECRUITING | 232 | Sep 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every YARW program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Zeronda TylerOfficer (CHIEF FINANCIAL OFFICER) | Disposition | -3,464 97,434 held | $0.65 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in YARW
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in YARW for Q2 2026. | ||||
Ownership Trends
YARW Short Interest
Shares sold short, counted twice a month.
1.69%
Short % of Float
of tradable shares sold short
141.9K
Shares Sold Short
+7.5% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
170.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How YARW ranks across every disease it competes in
Competitive Position is a premium feature
See how YARW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialYARW News
-YARW
Nov 12, 2026▲ +8.8%on this news
Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience reported its third quarter 2026 financial results, highlighting ongoing enrollment in the Phase 2a/2b trial for YB-101, an anti-TSHR antibody for Graves' disease. The company completed a $172.5 million public offering, strengthening its financial position. Topline results from the trial are anticipated in the second half of 2027.
Read more →-YARW
Nov 2, 2026▼ -9.9%on this news· ran to -32% by day 3
Yarrow Bioscience Announces Participation in November Investor Events
Yarrow Bioscience announced its participation in several investor conferences in November 2026. The events include the Guggenheim Securities Healthcare Innovation Conference and the Stifel Healthcare Conference. The company aims to discuss its pipeline and developments, particularly its anti-thyroid stimulating hormone receptor monoclonal antibody, YB-101.
Read more →-YARW
Sep 14, 2026Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Yarrow Bioscience has successfully closed its underwritten public offering, raising $172.5 million by selling 6,634,615 shares at $26.00 each. This includes the full exercise of the underwriters' option for an additional 865,384 shares. The funds will support the company's focus on developing therapies for autoimmune thyroid diseases.
Read more →-YARW
Sep 11, 2026▼ -5%on this newsshared move
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Yarrow Bioscience has announced the pricing of its underwritten public offering, selling 5,769,231 shares of common stock at $26.00 per share. This offering is expected to raise approximately $150 million for the company. Yarrow focuses on developing transformative therapies for autoimmune thyroid diseases.
Read more →-YARW
Sep 10, 2026▼ -5%on this newsshared move
Yarrow Bioscience Announces Proposed Underwritten Public Offering
Yarrow Bioscience, a clinical-stage biotechnology firm, has announced a proposed underwritten public offering of its common stock. The offering may include pre-funded warrants for certain investors. This move aims to bolster the company's financial resources as it develops therapies for autoimmune thyroid diseases.
Read more →-YARW
Aug 13, 2026Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience has announced its financial results for the second quarter of 2026. The report includes insights into the company's performance and ongoing business developments. This update reflects Yarrow's commitment to transparency and stakeholder engagement.
Read more →-YARW
Dec 15, 2025GenSci and RTW Announce Strategic Partnership on Anti-TSHR Antibody GS-098 (YB-101) for Graves’ Disease and Thyroid Eye Disease, With Global Ex-China Development Being Led by Yarrow Bioscience
GenSci and Yarrow Bioscience have formed a strategic partnership to develop GS-098 (YB-101), a monoclonal antibody for Graves' disease and thyroid eye disease. The agreement grants Yarrow exclusive global rights outside of China, with GenSci retaining rights within China. The deal includes a $70 million upfront payment and potential total payments of up to $1.365 billion. This collaboration aims to address significant unmet medical needs in autoimmune disorders.
Read more →About Yarrow Bioscience, Inc.
Headquarters470 JAMES STREET, SUITE 007, NEW HAVEN, CT, 06513
BIOPHARMAWATCH ELITE
Trade the next YARW catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime